Canaccord analyst Whitney Ijem reiterated a Buy rating and $227.00 price target on Palvella Therapeutics (NASDAQ: PVLA).The analyst commented: "Following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE